U.S. Capital Wealth Advisors LLC Acquires 238 Shares of Zoetis Inc. (NYSE:ZTS)

U.S. Capital Wealth Advisors LLC lifted its stake in Zoetis Inc. (NYSE:ZTS) by 2.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 9,331 shares of the company’s stock after purchasing an additional 238 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Zoetis were worth $1,520,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in the stock. Darwin Wealth Management LLC purchased a new position in Zoetis during the 3rd quarter valued at about $31,000. First Personal Financial Services purchased a new position in Zoetis during the third quarter valued at approximately $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis during the 3rd quarter worth approximately $33,000. Dunhill Financial LLC lifted its stake in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Fortitude Family Office LLC boosted its holdings in Zoetis by 1,387.5% in the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after purchasing an additional 222 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ZTS. UBS Group initiated coverage on Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Morgan Stanley decreased their price objective on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. JPMorgan Chase & Co. lifted their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, Leerink Partners initiated coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $215.00.

Zoetis Stock Up 0.2 %

ZTS opened at $172.24 on Wednesday. The company has a market cap of $77.71 billion, a P/E ratio of 32.38, a P/E/G ratio of 2.72 and a beta of 0.90. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53. The business’s 50-day moving average price is $169.48 and its 200-day moving average price is $179.39. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the previous year, the company posted $1.36 earnings per share. The business’s revenue was up 11.6% on a year-over-year basis. On average, equities analysts expect that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be given a dividend of $0.50 per share. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 annualized dividend and a yield of 1.16%. This is a boost from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio is presently 37.59%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.